Dong Y, Deng LJ, Li MM. Metachronous mixed cellularity classical Hodgkin’s lymphoma and T-cell leukemia/lymphoma: A case report. World J Clin Cases 2021; 9(27): 8177-8185 [PMID: 34621878 DOI: 10.12998/wjcc.v9.i27.8177]
Corresponding Author of This Article
Lai-Jun Deng, MS, Staff Physician, Department of Hematology, Weifang Hospital of Traditional Chinese Medicine, No. 1055 Weizhou Road, Kuiwen District, Weifang 261000, Shandong Province, China. denglaijun1982@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 26, 2021; 9(27): 8177-8185 Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8177
Metachronous mixed cellularity classical Hodgkin’s lymphoma and T-cell leukemia/lymphoma: A case report
Yang Dong, Lai-Jun Deng, Mi-Mi Li
Yang Dong, Department of Clinical Pharmacy, Weifang Hospital of Traditional Chinese Medicine, Weifang 261000, Shandong Province, China
Lai-Jun Deng, Department of Hematology, Weifang Hospital of Traditional Chinese Medicine, Weifang 261000, Shandong Province, China
Mi-Mi Li, Department of Pathology, Weifang Hospital of Traditional Chinese Medicine, Weifang 261000, Shandong Province, China
Author contributions: Dong Y designed the research study; Deng LJ performed the research and wrote the manuscript; Li MM analyzed the data; all authors have read and approve the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors do not have any possible conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lai-Jun Deng, MS, Staff Physician, Department of Hematology, Weifang Hospital of Traditional Chinese Medicine, No. 1055 Weizhou Road, Kuiwen District, Weifang 261000, Shandong Province, China. denglaijun1982@163.com
Received: April 12, 2021 Peer-review started: April 20, 2021 First decision: July 5, 2021 Revised: July 13, 2021 Accepted: August 23, 2021 Article in press: August 23, 2021 Published online: September 26, 2021 Processing time: 157 Days and 1.4 Hours
Abstract
BACKGROUND
The development of peripheral T-cell lymphoma (PTCL) after chemotherapy for Hodgkin’s lymphoma (HL) is rare, and highly aggressive TCL/leukemia has not been reported to date. The relationship between HL and PTCL needs further exploration to understand the pathogenesis of metachronous lymphoma (ML) and find effective treatment options. We report a patient with ML, whose biopsy of a right cervical lymph node initially confirmed classical HL (CHL).
CASE SUMMARY
We report a patient with ML, whose biopsy of a right cervical lymph node initially confirmed CHL, with typical reed–sternberg cells expressing CD30 and PAX-5. T-cell leukemia/lymphoma occurred 3 years after treatment, and a lymph node biopsy at the onset confirmed PTCL, nonspecific type, expressing CD3, CD4 and CD8. The patient was treated with standard doses of chemotherapy, programmed cell death-ligand 1 monoclonal antibody, and chidamide, all of which failed to achieve complete remission. The patient was diagnosed with refractory state, and eventually died of leukocyte stasis.
CONCLUSION
The accuracy of the diagnosis needs to be confirmed when chemotherapeutic drugs are not effective.
Core Tip: We report a patient with metachronous lymphoma. The development of peripheral T-cell lymphoma (TCL) after chemotherapy for Hodgkin’s lymphoma is rare, and highly aggressive TCL/leukemia has not been reported to date. We reviewed the literature and discussed whether immunodeficiency and malignant transformation of reactive T-cells may be major factors contributing to the development of TCL/ leukemia.
